about
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesPositron emission tomography to assess hypoxia and perfusion in lung cancerBatch-reactor microfluidic device: first human use of a microfluidically produced PET radiotracer.Molecular mechanisms of hypoxia in cancer.Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CTPreclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.Gene expression and hypoxia in breast cancer.A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRepeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trialEvaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancerFunctional MRI for radiotherapy dose painting.Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer.In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.Imaging hypoxia to improve radiotherapy outcome.Role of (18)F-FDG PET-CT in head and neck squamous cell carcinomaPositron emission tomography radiotracers for imaging hypoxia.Molecular imaging of tumor hypoxia with positron emission tomography.Current molecular imaging positron emitting radiotracers in oncology.Kinetic modeling in PET imaging of hypoxia.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.Radiopharmaceuticals as probes to characterize tumour tissue.Molecular imaging of hypoxia in non-small-cell lung cancer.Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.Hypoxia as a Biomarker and for Personalized Radiation Oncology.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine.Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging.Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia.Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.Clinical PET imaging of tumour hypoxia in lung cancerTherapeutic approaches to gastroesophageal junction adenocarcinomas
P2860
Q27025579-83A565E3-C474-41E7-A910-0FA2EA7127B1Q27026940-099F9AC0-3B6A-4E11-AFD5-19D037EEEC44Q30542885-B1A6584E-8673-4BE2-B011-C938201FFCB6Q33705108-AD3345A6-5350-47C7-9561-FE463CCA3A11Q34471063-9E63869F-064B-47FB-960A-66869F5155C4Q35198160-AF380B17-669F-4828-8598-EA84A92C717BQ35614451-09BB34A3-8D4C-4726-87A8-E9752B8C67E0Q36106434-06700FEA-144B-4915-A610-7842C4E29FA5Q36109283-4C4DDBD0-101F-4E22-8143-07AD05D73870Q37306472-6E1B2EF1-A6EA-4C2D-A1E3-09F267882DD4Q37467524-655C23F7-D0BB-446C-BED7-FF0A00750B7CQ37496776-9BAF67BE-F09D-497D-A0AE-87E3DD61A0C4Q37581964-5406FC12-B5FD-42BF-A56A-609E6757AB7DQ38040666-912F2E5A-C199-4793-A934-96A12F2F2A38Q38059626-15A1BCA1-B662-4578-B30B-D10F2A994F8AQ38101933-8F0DB194-C3E2-4820-817C-B8B6AB42E99AQ38166980-5E43A2A2-5D2E-4F98-9692-549220C0AB06Q38199721-0AFF97B9-7574-456F-92CA-F5F2CDA0CDBFQ38217835-0249D755-8A65-4B74-91DE-646DA17EB018Q38253648-27FE0AAA-657B-4163-983A-35049972F32BQ38263008-2F5297E5-FDF9-4523-8050-95EF5B9B814DQ38342458-5D8FDA8B-2DC5-4431-83E8-1229F0221832Q38363234-DF529BC8-06B9-4111-996A-D5CD8004B3E1Q38401218-4FB90BB0-2167-424A-AD60-889D9B358B6CQ38418282-4F1AF6E0-2398-43F6-9486-871B3F4230C8Q38608607-F15A23B2-9AD9-4FA3-AD99-F70C06574C08Q38869433-E7DC834C-8DC8-4E6A-95E7-563A4B02A1E1Q39668588-ADEAECE7-EB8B-4791-9A05-A515DFA0CBCBQ40513193-150761E5-7EEF-441E-B843-4BF0498791D4Q42060540-A1E76220-4CA0-4934-BD1D-52675C2F95A9Q47591784-2378E5E3-8A19-4C23-BE89-FACDFDFF2478Q50575883-7EEBC593-E84B-4463-AB87-F89F7CF625DEQ51487132-6C7D4CB7-B2DF-43D7-BABA-09AC033A8B4BQ52629217-F19FFAF1-8647-4897-8A33-32C623D20758Q57780509-A67DF0E2-F5D3-45FB-9712-15242FB3FC9DQ58484627-A2B63E35-510B-46AC-A559-B2336C0C1BC8
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@en
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@nl
type
label
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@en
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@nl
prefLabel
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@en
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@nl
P2093
P1476
PET imaging of hypoxia using [18F]HX4: a phase I trial.
@en
P2093
Anne-Marie C Dingemans
Boudewijn Brans
Guus A van Dongen
Hartmuth Kolb
Hugo J W L Aerts
James Zhang
Judith van Loon
Ludwig Dubois
Marco H M Janssen
Michel Ollers
P2888
P304
P356
10.1007/S00259-010-1437-X
P577
2010-04-06T00:00:00Z